Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06885034 · ClinicalTrials.gov registry record · Phase 1
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
A Phase 1 study of Gastrointestinal Neoplasms, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT06885034: Recruiting Phase 1 study of Gastrointestinal Neoplasms, sponsored by GlaxoSmithKline.
NCT06885034 is a Phase 1 study of Gastrointestinal Neoplasms that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 320 participants, below the 940-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06885034, a Phase 1 study of Gastrointestinal Neoplasms, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Primary Outcome
Confirmed ORR is defined as the proportion of participants who have achieved best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by investigator, according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Conditions Studied
Interventions
- BIOLOGICAL GSK5764227
Study Locations (20)
Other
- GSK Investigational Site - Bonheiden
- GSK Investigational Site - Brussels
- GSK Investigational Site - Leuven
- GSK Investigational Site - Roeselare
- GSK Investigational Site - Porto Alegre
- GSK Investigational Site - São Paulo
- GSK Investigational Site - Teresina
- GSK Investigational Site - Paris
- GSK Investigational Site - Paris
California
- GSK Investigational Site - Los Alamitos
- GSK Investigational Site - Whittier
Texas
- GSK Investigational Site - Houston
- GSK Investigational Site - San Antonio
Victoria
- GSK Investigational Site - Heidelberg
- GSK Investigational Site - Melbourne
New York
- GSK Investigational Site - New York
North Carolina
- GSK Investigational Site - Durham
Washington
- GSK Investigational Site - Wenatchee
Ontario
- GSK Investigational Site - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2025-06-11 |
| Est. Completion | 2028-06-23 |
| Phase | Phase 1 |
What NCT06885034 shows while recruiting
NCT06885034 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 940-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Gastrointestinal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which GSK5764227 is the first listed.
NCT06885034 names 20 study sites across 9 states, led by Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06885034 about?
NCT06885034 is a clinical study titled "A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed". This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
What is the current status of trial NCT06885034?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2025-06-11. Estimated completion is 2028-06-23.
What conditions does trial NCT06885034 study?
This clinical trial studies the following conditions: Gastrointestinal Neoplasms.
What interventions are being tested in trial NCT06885034?
The interventions under investigation include: GSK5764227 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06885034?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06885034 being conducted?
This trial has 20 study locations across California, New York, North Carolina, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06885034's enrollment target sits among peer trials
320 6th of 12 higher than 7 of 12 other Gastrointestinal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastrointestinal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
RECRUITING · Phase 1
-
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
COMPLETED · Phase 1
-
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
RECRUITING · Phase 3
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI